Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan Prilosec Litigation Ongoing; Omeprazole Sales Up In Fourth Quarter

This article was originally published in The Tan Sheet

Executive Summary

Mylan Labs continues to pursue litigation against Procter & Gamble over the marketing of Prilosec OTC as the company attempts to shield its growing Rx omeprazole business from OTC competition

You may also be interested in...

Prilosec OTC Bioequivalence To Rx Version “Has No Impact” – P&G

The lack of bioequivalence between Prilosec OTC (omeprazole) and Rx Prilosec is irrelevant to the product's OTC status because FDA approved the OTC version's toxicological profile as part of its review, Procter & Gamble maintains

Sanofi-Aventis Combo Leaves Allegra In Rx Territory For Now

Allegra's status as a prescription-only drug appears to be secure in the near-term now that Aventis has accepted Sanofi-Synthelabo's sweetened hostile bid for the company

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts